Antiphospholipid syndrome, antiphospholipid antibodies, and stroke.
Review published in International journal of stroke : official journal of the International Stroke Society (2023)
Abstract
Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disease with heterogeneous clinicopathological manifestations and is a well-established cause of acute ischemic stroke (AIS) and transient ischemic attack (TIA), particularly in younger patients. There is growing recognition of a wider spectrum of APS-associated cerebrovascular lesions, including white matter hyperintensities, cortical atrophy, and infarcts, which may have clinically important neurocognitive sequalae. Diagnosis of APS-associated AIS/TIA requires expert review of clinical and laboratory information. Management poses challenges, given the potential for substantial morbidity and recurrent thrombosis, additional risk conferred by conventional cardiovascular risk factors, and limited evidence base regarding optimal antithrombotic therapy for secondary prevention. In this review, we summarize key features of APS-associated cerebrovascular disorders, with focus on clinical and laboratory aspects of diagnostic evaluation. The current status of prognostic markers is considered. We review the evidence base for antithrombotic treatment in APS-associated stroke and discuss uncertainties, including the optimal intensity of anticoagulation and efficacy of direct oral anticoagulants. Clinical practice recommendations are provided, covering antithrombotic treatment, supportive management, and options for anticoagulant-refractory cases, and we highlight the benefits of adopting a considered, multidisciplinary team approach.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disease with heterogeneous clinicopathological manifestations and is a well-established cause of acute ischemic stroke (AIS) and transient ischemic attack (TIA), particularly in younger patients. There is growing recognition of a wider...
Por qué esto importa para la hirudoterapia
Esta revisión resume los aspectos clínicos y de laboratorio del síndrome antifosfolipídico (SAF) asociado con ictus y accidentes isquémicos transitorios, centrándose en la evaluación diagnóstica y en las estrategias de tratamiento antitrombótico. Se discuten los desafíos de la intensidad óptima de la anticoagulación y la limitada base de evidencia respecto a la eficacia de los anticoagulantes orales directos para la prevención secundaria en esta enfermedad autoinmune protrombótica. El resumen proporciona recomendaciones de práctica clínica estrictamente para tratamientos farmacológicos convencionales, incluyendo opciones para casos refractarios a anticoagulantes. No menciona sanguijuelas, hirudoterapia ni el secretoma de la sanguijuela, lo que hace que su conexión con la Sociedad Americana de Hirudoterapia sea estrictamente indirecta y limitada al manejo general de la trombosis.
Citación
Antiphospholipid syndrome, antiphospholipid antibodies, and stroke.
Mittal et al. · International journal of stroke : official journal of the International Stroke Society, 2023
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026